TLSA Tiziana Life Sciences PLC ADS

Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference

Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference

NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York.

Matthew W. Davis M.D., RPh, will be presenting at 2.30 p.m. ET on October 26th. Interested parties can register to attend . Dr Davis will also be holding one-on-one investor meetings throughout the day.

The presentation will also be live-streamed at the following .

About Tiziana Life Sciences Ltd

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

About The ThinkEquity Conference

The ThinkEquity Conference will gather industry insiders, investors and leading executives from around the world on October 26th in New York. Attendees can expect a full day of company presentations, panel discussions, one-on-one investor meetings and more.

Featured sectors include AI/Big data technology, Biotechnology, EV/EV Infrastructure, Metals & Mining and Oil & Gas.

To register to attend The ThinkEquity Conference, please follow this .

For further information:

Hana Malik

Business Development and Investor Relations Manager

+44 (0) 207 495 2379

Source: Tiziana Life Sciences Ltd



EN
19/10/2022

Underlying

TLSATiziana Life Sciences PLC ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tiziana Life Sciences PLC ADS

 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Announces Acquisition of Shares by Executive Cha...

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 97,687 common shares, bringing his total holding to 43,374,830 common shares, which is 36.08% of issued share capital. About Foralumab ...

22h / 52m 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Executive Chairman and Founder, Gabriele Cerrone will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony, will be held from 3:45 PM to 4:15 PM ET, celebrates Tiziana's ongoing advancements i...

December 17, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clini...

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces tha...

December 17, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive ...

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848. About Foralumab Foralumab, a f...

December 15, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of the proposed public offering of common shares due to market conditions. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sal...

December 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch